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Confirmation of a metastasis-
specific microRNA signature in 
primary colon cancer
Robert R. J Coebergh van den Braak  1, Anieta M. Sieuwerts  2,3, Zarina S. Lalmahomed1, 
Marcel Smid2, Saskia M. Wilting2, Sandra I. Bril1,2, Shanshan Xiang1,2, Michelle van der Vlugt-
Daane2, Vanja de Weerd2, Anne van Galen2, Katharina Biermann4, J. Han J. M van Krieken5, 
Wigard P. Kloosterman6, John A. Foekens2, MATCH study group*, John W. M. Martens  2,3 & 
Jan N. M. IJzermans1
The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant 
therapy may allow the clinical approach to be tailored for these patients based on an understanding of 
tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response 
in colorectal cancer. Recently, a 2-microRNA signature (let-7i and miR-10b) was proposed to identify 
colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value 
of this signature and additional candidate microRNAs in an independent, clinically well-defined, 
prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without 
and stage III colon cancer with adjuvant treatment. The 2-microRNA signature specifically predicted 
hepatic recurrence in the stage I-II group, but not the overall ability to develop distant metastasis. The 
addition of miR-30b to the 2-microRNA signature allowed the prediction of both distant metastasis and 
hepatic recurrence in patients with stage I-II colon cancer who did not receive adjuvant chemotherapy. 
Available gene expression data allowed us to associate miR-30b expression with axon guidance and 
let-7i expression with cell adhesion, migration, and motility.
Colorectal cancer (CRC) is the second most common malignancy in the Western world, with nearly 450,000 new 
cases in Europe in 20121. As in most solid cancers, histological tumour staging (TNM) is currently the best deter-
minant for prognosis and treatment. The current treatment for colon cancer is surgery alone for stages I and II 
and surgery followed by adjuvant chemotherapy for stage III. Despite treatment, up to 21% of patients with stage 
I-II colon cancer and up to 40% of patients with stage III colon cancer will develop metastatic disease after cura-
tive surgery2,3. Therefore, prognostic biomarkers complementing the TNM classification are urgently needed4,5. 
The only biomarker currently used to predict the prognosis and response to therapy in resectable colon cancer is 
microsatellite instability (MSI), a phenotype associated with a favourable prognosis compared to microsatellite 
stable (MSS) tumours.6
MicroRNAs (miRNAs) are a group of short noncoding RNAs that regulate gene expression at the 
post-transcriptional level7. In cancer, miRNAs play a central role in key pathways. In CRC, a growing number 
of miRNAs have been connected to different steps of tumourigenesis and been proposed as markers of prog-
nosis or the treatment response8. Recently, Hur et al. identified six miRNAs as potential markers of the devel-
opment of metastases in CRC patients (miR-320, miR-221, miR-30b, miR-10b, miR-885-5p, and let-7i) via a 
metastasis-specific miRNA biomarker discovery approach showing differential expression of these six miRNAs 
between primary CRC and paired metastatic liver tissues9. Two of these miRNAs (miR-10b and let-7i) measured 
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in primary tumours were associated with the development of distant metastases. The combined expression of 
these two miRNAs identified a group of patients that remained entirely free of distant metastases.
In this study, we aimed to assess the prognostic value of the above-mentioned miRNAs and the 2-miRNA 
metastasis-specific signature in an independent, clinically well-defined, prospectively collected cohort of primary 
colon cancers. Patients with lymph node negative (LNN) colon cancer who did not receive systemic adjuvant 
chemotherapy (untreated) and patients with lymph node positive (LNP) colon cancer who received adjuvant 
chemotherapy were analysed separately to distinguish between the natural course of the disease (pure prognosis) 
and prognosis during adjuvant chemotherapy.
Results
Association of miRNA expression levels with clinical and histopathological characteristics. 
The total cohort comprised 232 patients: 155 patients with LNN primary colon cancer and 77 patients with LNP 
primary colon cancer. First, we assessed the distribution of mRNA expression for each miRNA and correlations 
between the expression levels of the miRNAs (Supplementary Fig. S1). The only miRNA for which expression 
did not follow a normal distribution was miR-885-5p (P < 0.001). All miRNAs significantly positively correlated 
with three or more of the six assessed miRNAs. However, only poor to moderate associations were observed 
(Spearman’s rho 0.13–0.33, P < 0.001–P = 0.044; Supplementary Fig. S1). Next, possible associations between 
miRNA expression and clinical and histopathological characteristics were assessed. Importantly, most of the sig-
nificant differences in miRNA expression in the total group were derived from differences in the LNN group and 
not the smaller LNP group. As we were primarily interested in the association with pure disease prognosis, the 
LNN subgroup was the main focus of further analyses. The associations between clinical and histopathological 
features of the LNN group are shown in Table 1, the total group in Supplementary Table S1a, and the LNP group 
in Supplementary Table S1b.
Expression of miR-221, miR-30b, and miR-885–hyp5p was significantly lower, whereas expression of miR-10b 
was significantly higher in MSI tumours than MSS tumours (Table 1). Expression of miR-221 and miR-30b was 
significantly lower and miR-10b significantly higher in left-sided tumours than right-sided tumours. In addition 
to the associations of miRNAs with these two clinically important characteristics, expression of let-7i was signifi-
cantly lower in stage II tumours than stage I tumours.
N (%) miR-320
P 
value miR-221 P value miR-30b
P 
value P value miR-885–5p P value let-7i P value
Gender Female 73 (47.1%)
−4.50 
(−5.01–4.10) 0.94
−1.78 
(−2.56–1.18) 0.42
−1.79 
(−2.37–1.27) 0.025
−2.55 
(−3.12–1.80) 0.09
−11.20 
(−13.00–10.32) 0.96
−2.97 
(−3.45–2.28) 0.14
Male 82 (52.9%)
−4.55 
(−4.97–3.99)
−1.77 
(−2.39–0.97)
−1.59 
(−1.99–1.14)
−2.68 
(−3.18–2.15)
−11.39 
(−12.74–10.48)
−3.16 
(−3.87–2.48)
Age 155 (100%) −0.05 0.57 −0.13 0.10 0.01 0.87 0.09 0.25 0.02 0.78 0.07 0.39
Tumour 
stage Stage I
57 
(36.8%)
−4.61 
(−5.01–4.03) 1.00
−1.78 
(−2.45–0.88) 0.65
−1.55 
(−1.97–1.07) 0.13
−2.62 
(−3.29–1.90) 0.96
−11.21 
(−12.88–10.09) 0.16
−2.59 
(−3.55–2.09) 0.037
Stage II 98 (63.2%)
−4.49 
(−4.99–4.08)
−1.77 
(−2.51–1.16)
−1.75 
(−2.17–1.35)
−2.66 
(−3.13–2.02)
−11.39 
(−13.00–10.52)
−3.15 
(−3.61–2.66)
T status T2 57 (36.8%)
−4.61 
(−5.01–4.03) 1.00
−1.78 
(−2.45–0.88) 0.65
−1.55 
(−1.97–1.07) 0.13
−2.62 
(−3.29–1.90) 0.96
−11.21 
(−12.88–10.09) 0.16
−2.59 
(−3.55–2.09) 0.037
T3 98 (63.2%)
−4.49 
(−4.99–4.08)
−1.77 
(−2.51–1.16)
−1.75 
(−2.17–1.35)
−2.66 
(−3.13–2.02)
−11.39 
(−13.00–10.52)
−3.15 
(−3.61–2.66)
Nodal 
status N0
127 
(81.9%)
−4.47 
(−4.95–4.01) 0.23
−1.77 
(−2.51–1.13) 0.72
−1.75 
(−2.13–1.32) 0.053
−2.61 
(−3.11–1.91) 0.15
−11.34 
(−13.00–10.48) 0.56
−3.05 
(−3.54–2.38) 0.48
N0 < 10 
nodes
28 
(18.1%)
−4.72 
(−5.14–4.13)
−1.71 
(−2.46–0.67)
−1.40 
(−1.99–0.91)
−2.73 
(−3.37–2.06)
−11.28 
(−12.94–9.50)
−3.12 
(−3.96–2.36)
Tumour 
grade Good
13 
(8.4%)
−4.38 
(−4.91–3.99) 0.77
−1.59 
(−1.97–1.06) 0.21
−1.54 
(−1.95–1.26) 0.95
−2.74 
(−3.29–1.89) 0.98
−11.61 
(−13.00–10.50) 0.28
−3.01 
(−3.86–2.39) 0.51
Moderate 130 (83.9%)
−4.52 
(−5.02–4.03)
−1.82 
(−2.50–1.14)
−1.74 
(−2.13–1.26)
−2.65 
(−3.13–1.95)
−11.32 
(−13.00–10.43)
−3.12 
(−3.56–2.36)
Poor 9 (5.8%)
−4.58 
(−5.41–4.22)
−2.35 
(−3.58–1.21)
−1.73 
(−2.58–1.01)
−3.00 
(−3.27–2.31)
−11.64 
(−12.91–10.60)
−2.87 
(−3.66–2.44)
Other 3  (1.9%)
−4.27 
(−4.71–)
−1.77 
(−2.16–)
−1.08 
(−1.52–)
−1.59 
(−2.26–)
−9.15 
(−10.49–)
−2.55 
(−3.00–)
Location Right 79 (51.0%)
−4.49 
(−4.88–4.09) 0.76
−2.16 
(−2.69–1.47) 0.001
−1.82 
(−2.16–1.46) 0.029
−2.49 
(−2.77–1.78)  <0.001
−11.22 
(−13.00–10.41) 0.70
−3.16 
(−3.59–2.37) 0.55
Left 76 (49.0%
−4.58 
(−5.11–4.02)
−1.48 
(−2.19–1.09)
−1.56 
(−1.97–1.09)
−2.94 
(−3.41–2.29)
−11.35 
(−12.79–10.45)
−3.03 
(−3.54–2.44)
MSI-
statusa MSI
34 
(22.1%)
−4.50 
(−4.80–4.00) 0.44
−2.53 
(−3.06–2.10)  <0.001
−2.00 
(−2.20–1.60) 0.007
−2.12 
(−2.63–1.45)  <0.001
−12.33 
(−13.00–10.58) 0.011
−3.01 
(−3.34–2.46) 0.50
MSS 120 (77.9%)
−4.51 
(−5.08–4.05)
−1.61 
(−2.30–0.94)
−1.61 
(−1.99–1.15)
−2.73 
(−3.24–2.12)
−11.21 
(−12.65–10.26)
−3.08 
(−3.68–2.35)
Table 1. Clinical and histopathological characteristics of the LNN patients. Data are given as median 
(interquartile range). aOne missing value.
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let-7i, MiR-30b, and miRNA signature as prognostic markers of clinical outcome. The prognostic 
value of the six miRNAs was assessed using expression as a continuous variable in a univariate Cox regression 
model (Table 2). Let-7i expression was significantly associated with hepatic metastasis free survival (HFS) (hazard 
ratio [HR] = 0.32, 95% confidence interval [CI] = 0.17–0.60, P < 0.001). In contrast to the findings reported by 
Hur et al., miR-10b was not significantly associated with any of the clinical endpoints. However, the expression 
of miR-30b was significantly associated with metastasis free survival (MFS) and HFS (HR = 2.13, 95% CI = 1.22–
3.72, P = 0.008 and HR = 2.77, 95% CI = 1.24–6.18, P = 0.013, respectively). None of the other miRNAs were 
associated with MFS or HFS, and none of the miRNAs were significantly associated with overall survival (OS).
The significant associations were visualized by Kaplan Meier analysis dividing the expression levels of let-7i 
and miR-30b into quartiles (Fig. 1), showing a split course for Q1–2 (below median) and Q3–4 (above median). 
The median expression levels were used to assess the prognostic value of the original 2-miRNA signature in our 
cohort (let-7i high and miR-10b low vs. let-7i low and/or miR-10b high). The 2-miRNA signature was significantly 
associated with HFS (5-year survival 100% vs. 89.3%, P = 0.04; Fig. 2a) but did not demonstrate a significant dif-
ference for MFS (Fig. 2b) or OS (Fig. 2c).
N (%)
Univariate Multivariate
MFS (25 events) HFS (12 events) OS (23 events) MFS (25 events) HFS (12 events) OS (23 events)
HR (95% CI)
P 
value HR (95% CI) P value HR (95% CI)
P 
value
HR  
(95% CI)
P 
value
HR  
(95% CI)
P 
value
HR  
(95% CI)
P 
value
mRNA 
expression miR-320 155 (100%)
0.80 
(0.49–1.31) 0.38
0.64 
(0.32–1.26) 0.20 0.86(0.51–1.47) 0.59
miR-221 155 (100%) 1.37 (0.94–1.98) 0.098
0.91 
(0.53–1.57) 0.75 0.83(0.55–1.26) 0.38
miR-30b 155 (100%) 2.13 (1.22–3.72) 0.01
2.77 
(1.24–6.18) 0.013 1.39(0.74–2.59) 0.31
miR-10b 155 (100%) 0.99 (0.61–1.61) 0.97
0.70 
(0.35–1.38) 0.30 0.99(0.59–1.65) 0.97
miR-
885–5p 155 (100%)
0.90 
(0.68–1.18) 0.44
0.84 
(0.55–1.27) 0.40 0.80(0.59–1.09) 0.15
let-7i 155 (100%) 0.69 (0.45–1.07) 0.10
0.32 
(0.17–0.60) <0.001 0.94(0.54–1.30) 0.43
Gender Female 73 (47.1%) 1 1 1
Male 82 (52.9%) 1.41 (0.63–3.14) 0.40
1.84 
(0.55–6.11) 0.32 2.23(0.92–5.42) 0.08
Age 155 (100%) 1.004 (0.96–1.05) 0.88
1.01 
(0.94–1.09) 0.75 1.08(1.02–1.14) 0.01
Tumour 
stage Stage I 57 (36.8%) 1 1 1
Stage II 98 (63.2%) 1.51 (0.63–3.61) 0.36
1.17 
(0.35–3.90) 0.79 1.07(0.45–2.53) 0.88
T status T2 57 (36.8%) 1 1 1
T3 98 (63.2%) 1.51 (0.63–3.61) 0.36
1.17 
(0.35–3.90) 0.79 1.07(0.45–2.53) 0.88
Nodal 
status N0 127 (81.9%) 1 1 1 1 1 1
N0 < 10 
nodes 28 (18.1%)
1.20 
(0.45–3.20) 0.72
3.42 
(1.08–10.76) 0.04 1.51(0.59–3.86) 0.39
1.08 
(0.40–2.88) 0.88
2.91 
(0.92–9.19) 0.07
1.44 
(0.55–3.75) 0.45
Tumour 
grade Good 13 (8.4%) 1 1 1
Moderate 130 (83.9%) 1.01 (0.24–4.31) 0.99
0.91 
(0.12–7.19) 0.93 1.98(0.27–14.80) 0.51
Poor 9 (5.8%) 2.12 (0.35–12.69) 0.41
2.85 
(0.26–31.39) 0.39 4.47(0.46–43.17) 0.20
Otherb 3 (1.9%) — — —
Location Right 79 (51.0%) 1 1 1
Left 76 (49.0%) 1.91 (0.84–4.32) 0.12
1.08 
(0.35–3.33) 0.90 0.60(0.25–1.40) 0.24
MSI-
statusa MSI 34 (22.1%) 1 1 1
MSS 120 (77.9%) 3.46 (0.82–14.70) 0.09
30.43 
(0.1–9228.65) 0.24 0.48(0.21–1.11) 0.09
Modified 
signature low risk 79 (51.0%) 1 1 1 1 1 1
high risk 76 (49.0%) 2.73 (1.14–6.55) 0.02
11.19 
(1.45–86.69) 0.02 1.31(0.57–2.99) 0.52
2.72 
(1.13–6.53) 0.03
10.30 
(1.33–79.992) 0.03
1.24 
(0.53–2.87) 0.62
Table 2. Univariate and multivariate Cox regression analysis for the LNN group. aOne missing value; bthere 
were no events in this subgroup.
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As miR-30b was significantly associated with MFS and HFS (Fig. 1b and 1c, respectively) in our cohort, we 
explored whether miR-30b could contribute to the discriminating value of the signature. In a multivariate Cox 
regression model including the 2-miRNA signature and miR-30b expression split at the median level, miR-30b 
was significantly associated with MFS (HR = 3.65, 95% CI = 1.44–9.27, P = 0.007) and HFS (HR = 10.04, 95% 
CI = 1.30–77.78, P = 0.027) independent of the original signature. For both models, the log likelihood signifi-
cantly increased when adding miR-30b expression split at the median level (Δ log likelihood = 4.36, P = 0.003 and 
Δ log likelihood = 4.43, P = 0.003). Therefore, we added the miR-30b split at the median expression level to the 
original metastasis-specific miRNA signature (modified 3-miRNA signature), in which patients were categorized 
as low risk when having a tumour with at least two of the following: let-7i high, miR-10b low, and miR-30b low. 
All other patients were categorized as high risk. The modified 3-miRNA signature was significantly different in 
regards to MFS (5-year survival 90.2% vs. 75.5%, P = 0.019) and HFS (5-year survival 98.6% vs. 85.6%, P = 0.004; 
Figs 2a and b, respectively). In the total group, this modified signature also demonstrated a significant difference 
between patients in the ‘low risk’ and ‘high risk’ groups for both MFS (5-year survival 86.8% vs. 73.8%, P = 0.018) 
and HFS (5-year survival 97.0% vs. 86.2%, P = 0.004). However, the modified 3-miRNA signature did not corre-
late with OS in these groups or with any of the clinical endpoints in the LNP group.
Nodal status was the only traditional clinical factor significantly associated with disease outcome in the uni-
variate Cox regression analysis in both the LNN and total groups (Table 2 and Supplementary Table S2, respec-
tively). When adjusting for lymph node status in a multivariate Cox regression model, which was stratified in 
the LNN group into two groups based on the total number of assessed lymph nodes (cut-off = 10), the modified 
metastasis-specific 3-miRNA signature was still significantly associated with MFS (HR = 2.72, 95% CI = 1.13–
6.53, P = 0.025) and HFS (HR = 10.30, 95% CI = 1.33–79.99, P = 0.026) in the LNN group and HFS in the total 
group (HR = 5.07, 95% CI = 1.46–17.59, P = 0.011; Table 2 and Supplementary Table S2, respectively).
Pathway analysis. Pathway analysis showed that let-7i expression was associated with axon guidance, gly-
cosphingolipid and glycosaminoglycan biosynthesis, focal adhesion, extracellular matrix (ECM) receptor inter-
action, and regulation of the actin cytoskeleton, which are all related to cell adhesion, migration, and motility. 
Furthermore, we observed an association with the hedgehog, WNT, and transforming growth factor (TGF)-β 
signalling pathways (Supplementary Tables S3 and S4). Combined use of three independent target prediction 
Figure 1. Kaplan Meier estimates for the correlation between let-7i with HFS and miR-30b with MFS and HFS 
in the LNN group. Q1 = lowest quartile, Q4 = highest quartile.
Figure 2. Kaplan Meier estimates for the correlation between the original metastasis-specific signature (dashed 
line) and modified metastasis-specific signature (continuous line) for MFS, HFS, and OS.
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algorithms did not reveal any overlapping let-7i target genes involved in glycosphingolipid biosynthesis, gly-
cosaminoglycan biosynthesis, or the hedgehog signalling pathway. However, the axon guidance, focal adhesion, 
ECM receptor interaction, regulation of actin cytoskeleton, TGF-β signalling, and WNT signalling pathways do 
contain a number of genes predicted to be let-7i targets by all three algorithms (Supplementary Table S5). The 
expression of COL4A6 and FNDC3A, which are involved in focal adhesion and ECM receptor interactions, sig-
nificantly negatively correlated at the mRNA level to let-7i expression in the LNN and LNP samples. Expression of 
ACVR1C, part of the TGF-β signalling pathway, negatively correlated with let-7i only in LNP samples (P = 0.056).
Expression of miR-30b was associated with axon guidance and significantly negatively correlated with the 
expression of PPP3R1, NFAT5, and SEMA6B in this pathway (Supplementary Tables S3–5).
Notably, we observed more significant positive correlations between let-7i expression and its predicted targets 
in all significantly associated pathways, suggesting that the effect of let-7i on genes in these pathways are mostly 
indirect.
Discussion
Our study confirmed the clinical significance of measuring let-7i and the miRNA-signature as suggested by Hur 
et al. and have extended these findings to a well-defined independent cohort of patients with colon cancer. We 
showed that the expression of most of these miRNAs is different for MSI and MSS tumours and for left- and 
right-sided tumours. Furthermore, let-7i was expressed at a lower level in stage II colon cancer compared to stage 
I colon cancer. We validated let-7i as a prognostic marker but could not confirm miR-10b as a prognostic factor. 
In contrast, miR-30b was prognostic with regard to MFS and HFS. The original metastasis-specific 2-miRNA sig-
nature was significantly associated with HFS but not MFS. Therefore, we propose a modified metastasis-specific 
3-miRNA signature combining miR-10b, miR-30b, and let-7i, which identified groups with low and high risk in 
terms of MFS and HFS. Subsequent pathway analysis suggested an association between let-7i expression and cell 
adhesion, migration, and motility, and the hedgehog, WNT, and TGF-β signalling pathways. miR-30b expression 
was associated with axon guidance.
The findings with regard to differential expression of the miRNAs in MSI versus MSS and left-sided versus 
right-sided tumours suggest a different role of these miRNAs in hypermutated and non-hypermutated tumours, 
adding to our understanding of these biologically different entities. Although these characteristics were not 
included in the differential miRNA expression analysis by Hur et al., the findings are in line with accumulating 
evidence of the role of miRNAs in the pathogenesis of MSI tumours, such as the involvement of miR-21 and miR-
155 in the regulation of mismatch repair gene and protein expression10. Similarly, left- and right-sided tumours 
are reported to express miRNAs at different levels11,12. Our findings add to the fast expanding knowledge on the 
different roles of miRNAs in these biologically different entities. Furthermore, we found that let-7i expression was 
lower in stage II tumours compared to stage I tumours, which is line with Hur et al.’s findings and the tumour 
suppressing role of the let-7 family as described in the literature13.
Furthermore, low expression of let-7i was associated with poor HFS in our cohort of patients with LNN colon 
cancer who did not receive adjuvant chemotherapy, which confirmed the findings of Hur et al. We also found 
that high expression of miR-30b was associated with poor MFS and HFS, which was not observed by Hur et al., 
because miR-30b was not validated in the comparative analysis of primary CRC and matched metastatic liver 
tissues used for the identification of miRNAs that may hold prognostic potential in primary tumours. In our 
cohort, all patients had colon cancer, which may explain the different observations in our cohort. In contrast 
to Hur et al., we did not find a significant association or trend between the expression of miR-10b and any of 
the long-term clinical endpoints. Interestingly, Hur et al. showed that miR-10b is downregulated in metastatic 
liver tissue compared to primary CRC tissue, whereas it is upregulated in primary CRC versus normal tissue, 
and high expression of miR-10b is associated with poor MFS. This suggests that differential expression between 
primary and metastatic lesions does not always reflect the prognostic and/or predictive value in primary tumour 
lesions14–19. This may also explain the discrepancy in miR-30b between the absence of differential expression in 
their comparative analysis and the association with MFS/HFS in our cohort, although further studies are needed 
to confirm the latter.
Hur et al. also showed that their signature, consisting of miR-10b and let-7i, was associated with MFS in one 
cohort of primary colorectal cancers. Although this signature segregated our cohort of patients with LNN colon 
cancer into two groups with significantly different outcomes in terms of HFS, we did not find a significant dif-
ference in terms of MFS. Incorporation of miR-30b (modified signature) identified low and high risk groups that 
were clearly distinctive with regard to MFS and HFS. These results remained significant after correcting for nodal 
status. Next to nodal status, MSI was significantly associated with HFS in the LNN group. Furthermore, when 
correcting for MSI alone or together with nodal status in the LNN group, the modified metastasis-specific signa-
ture remained significantly associated with MFS and HFS (data not shown). However, due to the low number of 
events, these multivariable analyses should be interpreted with caution. Taken together, our results underline the 
prognostic value of let-7i and provide support for the prognostic value of the modified miRNA signature.
The different observations can be explained by differences in the patient cohorts used in the study by Hur et 
al. and the current study. The cohorts used by Hur et al. were heterogeneous with regard to tumour stage and 
tumour location (both colon and rectum were included), and no information was provided on pre-operative 
and postoperative local and systemic treatment9. This heterogeneity may explain, for example, the failure of val-
idating miR-30b in the comparative analysis, as miR-30b expression varies between colon and rectal cancers12; a 
well-defined prospective cohort of patients with colon cancer was used in the current study. Another explanation 
for the observed differences may be the cut-off used to dichotomize expression levels. Hur et al. used Youden’s 
index (i.e., the most optimal combination of sensitivity and specificity) to determine the cut-off value for the max-
imum potential effectiveness of miRNAs based on a specific outcome parameter20. Inherent to the dependency of 
the cut-off to the outcome parameter, patients may change from low risk to high risk depending on the outcome 
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of interest. In our cohort, the cut-off value based on Youden’s index was nearly identical to the median expression 
level, which is independent of the outcome parameter of interest and, per definition, gives two equally sized sub-
groups (data not shown). In their cohort, Youden’s index stratified the patients into two unequally sized groups 
(4.8% low let-7i expression and 21% low miR-10b expression); thus, the cut-off value based on Youden’s index was 
quite different from the median expression level. Therefore, future studies should explore the median expression 
level to assign patients to a low or high risk group. Lastly, differences in the material used (formalin-fixed paraffin 
embedded versus fresh frozen), RNA isolation, and/or assays used to measure miRNA expression may account 
for part of the observed differences.
The pathway analysis for let-7i and miR-30b revealed several interesting associations. Let-7i expression was 
associated with several pathways related to cell adhesion, migration, and motility. This is in line with the literature, 
which indicates that the expression of this miRNA is associated with the expression of genes in these pathways 
that are to known to be altered in carcinogenesis and involved in progression21,22. Activation of either LIN28A 
or LIN28B is thought to be responsible for global post-transcriptional downregulation of the let-7 family in can-
cer23. Furthermore, let-7i expression was associated with the hedgehog, WNT, and TGF-β signalling pathways. 
Interestingly, the let-7 family was shown to be involved in hedgehog-mediated drug resistance in lung cancer, 
which supports the observed association in our cohort24. Similarly, the let-7 family was shown to be involved in 
Wnt signalling in breast cancer, which again involves LIN2825. Lastly, high expression of let-7i was associated with 
increased TGF-β signalling, which plays a major role in the tumourigenesis of at least half of all CRCs in which 
inactivating mutations abolish the tumour suppressing effect of the TGF-β signalling pathway. Furthermore, 
decreased SMAD4 expression, a downstream target of TGF-β, is associated with poor prognosis in colon cancer, 
providing indirect evidence that inactivation of TGF-β signalling leads to the invasive behaviour of colon can-
cer26. Interestingly, TGF-β appears to convert from a tumour suppressor to a tumour promotor in more advanced 
stages of cancer, which is known as the TGF-β paradox27. A few studies have specifically addressed the association 
between let-7 and TGF-β expression, showing an inverse correlation28,29. However, these studies were performed 
in cell lines and a melanoma xenograft model, which may preclude extrapolation of these results to CRC in a clin-
ical setting. Using three prediction algorithms, 6% of the genes in the TGF-β signalling pathway were considered 
a potential target of let-7i. The positive correlation between tumour suppressor let-7i and genes involved in the 
TGF-β signalling pathway suggests that TGF-β has yet to go through this conversion, and both TGF-β and let-7i 
act as tumour suppressors. Interestingly, expression of ACVR1C was negatively associated with let-7i expression 
in only the LNP group, suggesting that these tumours may have gone through the conversion. The association 
with the above-mentioned pathways may also suggest that let-7i is linked to stromal content and plays an indirect 
role in TGF-β signalling in stromal cells, which is involved in in metastasis initiation30.
The miR-30 family has been studied extensively in the field of cancer research. In vitro, miR-30 family mem-
bers have been associated with several aspects of tumourigenesis, including cell migration, cell growth, cell inva-
siveness, and apoptosis31–39. Interestingly, both negative and positive associations with tumourigenesis have been 
described for miR-30 family members, including miR-30b, which precludes definitive conclusions. Contrasting 
associations have also been reported between the miR-30 family and tumour characteristics, such as tumour 
stage and tumour grade31,37,38,40–43. In terms of clinical outcome, defined as MFS and/or OS, miR-30 family mem-
bers have been described as markers of poor outcome in melanoma40, ovarian cancer32, prostate cancer35, and 
oesophageal cancer44, and as a tumour suppressive miRNA in breast cancer42, lung cancer45, CRC33, prostate 
cancer31, and ovarian cancer46. In our study, high miR-30b expression was associated with poor MFS and HFS. 
The pathway analysis mainly revealed a positive association between miR-30b expression and axon guidance. The 
genes traditionally described by their roles in axon guidance are important regulators of neuronal migration and 
positioning during embryonic development. However, they have been implicated in cancer cell survival, growth, 
invasion, and angiogenesis47,48. Very little is available in the current literature on the direct association between 
miR-30b and axon guidance. However, the target gene prediction we performed subsequent to the pathway anal-
ysis predicted that >11% of the genes listed in the ‘axon guidance’ pathway in KEGG were direct targets of miR-
30b. In support of this direct interaction, significant negative correlations between the expression of miR-30b 
and axon-guidance genes PPP3R1, NFAT5, and SEMA6B were observed in our cohort. Further research may be 
directed to investigate the possible role of miR-30b in axon guidance. These insights, combined with the fact that 
miR-30b was upregulated in patients in our cohort with a poor prognosis, may provide a rationale for investigat-
ing the miRNA as a therapeutic target.
Although overlapping predicted targets were found for the majority of let-7i- and miR-30b-associated path-
ways in three prediction algorithms, we observed many significantly positive correlations between let-7i and its 
predicted targets in our cohort. Thus, the effects of let-7i on the associated pathways are (partially) indirect, and 
functional studies are needed to confirm this. Overall, the observed associations suggest that let-7i and miR-30b 
may be relevant factors for cancer cells in their ability to move, potentially also involving their stromal compo-
nent, increasing their metastatic potential.
Our data suggest that let-7i, miR-30b, and a three-miRNA signature hold prognostic value in LNN colon 
cancers, although independent validation in a large cohort is needed. Ideally, further studies should include an 
analysis of the circulating serum levels of these miRNAs.
Methods
All aspects of the guidelines for REporting recommendations for tumour MARKer (REMARK) prognostic stud-
ies were followed, and the paper was written accordingly49. The study was conducted according to the Declaration 
of Helsinki. All procedures involving human subjects were approved by the Erasmus MC University Medical 
Centre Institutional Review Board (MEC 2007-088).
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Patient selection. Patients were selected from the MATCH cohort, an observational prospective multi-
centre cohort study conducted from 2007 onwards that includes patients undergoing curative surgery for CRC 
in one of seven participating hospitals in the Rotterdam region of the Netherlands. Patients provided written 
informed consent for the storage and use of biobank samples for research purposes and the collection of clinical 
data (Institutional Review Board number MEC 2007-088).
Additional inclusion criteria for this study were: inclusion date between 1 July 2007 and 1 July 2012, age 55–85 
years, stage I-II colon cancer without adjuvant chemotherapy or stage III colon cancer with adjuvant chemother-
apy, fresh frozen tissue with at least 40% invasive tumour cells available, and either recurrence of disease or at least 
30 months of disease-free follow-up (Fig. 3).
Sample collection and processing. Resected specimens from the primary tumours were transported to 
the pathology laboratory immediately following removal during surgery. Two to four samples of both the central 
and peripheral regions of the tumour and one or two adjacent non-tumour colon tissue samples were taken. 
The samples were fresh frozen with a maximum cold ischemia time of 2 hours. All samples were stored in liquid 
nitrogen.
RNA isolation, cDNA synthesis, and mRNA transcript quantification. A cryostat microtome set at 
−20 °C was used to cut the fresh frozen colon cancer and normal colon tissues (Thermo Scientific Microm HM 
560, Thermo Fisher Scientific, Inc.). A 5-µm section was cut before, during, and after sectioning for RNA isola-
tion. After haematoxylin-eosin (HE) staining, the sections were reviewed independently by two pathologists. The 
percentage of neoplastic cells, infiltrating immune cells, necrosis, and normal mucosa was scored in categories of 
0–5%, 6–10%, 11–20%, 21–30%, 31–40%, 41–50%, 51–60%, 61–70%, 71–80%, 81–90%, and 91–100% relative to 
other cells. Tumour classification and grading was determined using the WHO 2010 classification for carcinoma 
of the colon and rectum (WHO Press, World Health Organization, 20 Avenue Appia, Geneva, Switzerland).
Total RNA was isolated from 30-µm sections using RNA-Bee® according to the manufacturer’s instruc-
tions (Tel-Test, Inc., USA). The quality and quantity of the RNA was assessed using the MultiNA Microchip 
Electrophoresis system (Shimadzu, Kyoto, Japan) and Nanodrop ND-1000 (Thermo Scientific, Wilmington, 
USA), respectively.
The expression of the six miRNAs was quantified in a 9-plex miRNA assay protocol utilizing commercially 
available and validated TaqMan miRNA assays (Applied Biosystems, Thermo Scientific, USA) relative to the aver-
age of reference genes miRNA-16, RNU6B, and RNU44 in the same total RNA sample.
Briefly, 5 μL samples containing 20 ng/μL total RNA were reverse-transcribed for 30 min at 16 °C, 30 min 
at 42 °C, 5 min at 85 °C, and stopped at 4 °C in the presence of 18 nM of each of the nine TaqMan RT-primers 
in 1x RT buffer (Fermentas) supplemented with 0.65 mM of each dNTP (Fermentas), 0.25 U/μL RNAseout 
(Fermentas), 3.8 mM MgCl2 (Invitrogen) in the absence (negative control) or presence of 15 U/μL revertAid 
MLV H-minus RT (Fermentas). After the reverse transcription, the samples were diluted 20-fold in LoTE (3 mM 
Tris-HCl/0.2 mM EDTA, pH 8.0) prior to 40 cycles of individual qPCR reactions for each of the nine miRNA 
assays in the presence of TaqMan Master mix without UNG as advised by the manufacturer (Applied Biosystems, 
Thermo Scientific, USA). The specifics of the six target miRNA assays and three reference miRNA assays used to 
normalize the data are provided in Supplementary Table S6.
Microsatellite instability. Genomic DNA was extracted from 2 to 5 × 30 µm sections cut from between the 
sections used for RNA isolation (NucleoSpin Tissue kit, Macherey-Nagel, BIOKE, Leiden, the Netherlands). MSI 
status was determined by a fluorescent PCR-based assay in five mononucleotide repeat markers (BAT-25, BAT-26, 
NR-21, NR-24, and MONO-27; Promega MSI Analysis System) using 2 ng of PicoGreen-measured DNA. Quality 
and quantity were assessed by agarose gel electrophoresis, Nanodrop, and the Quant-iT PicoGreen dsDNA kit 
Figure 3. Diagram of patient selection.
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(Life Technologies). Two pentanucleotide repeat markers (Penta C and Penta D) were also included to detect 
potential sample mix-ups and/or contamination using the manufacturer’s protocol.
Pathway analysis. RNA sequencing data were available for 231 patients50. We used the STAR51 algorithm 
(version 2.4.2a) to align the RNA-seq data with the GRCh38 reference using the ‘–quantmode Genecounts’ option 
to obtain the raw read counts for each gene. Gene annotation was derived from gencode v23 (https://www.gen-
codegenes.org/). Next, the trimmed mean of M-values normalization52, as implemented in EdgeR53, was used to 
normalize the raw read count data. These data were used as the input in the pathway analysis.
For the miRNAs associated with long-term clinical outcomes in our cohort, the 50 tumours with the highest 
expression and 50 tumours with the lowest expression of each miRNA were grouped and used as input. Pathway 
analyses were performed using the R-package ‘global test’ with KEGG54. Importantly, only genes for which expres-
sion data were available were used as input. The Bonferroni-Holm method was used to correct all P values for 
multiple testing. Re-sampling (n = 1,000) was performed to determine the number of times a randomly selected 
group of genes of equal size was at least as significant as the true set of genes assigned to a pathway. The gene plots 
of pathways with a corrected P value < 0.05 and a re-sampling probability < 0.05 were reviewed. Three target gene 
prediction databases were used to identify genes within the selected pathways that were predicted to be poten-
tial targets of the respective miRNAs (Targetscan version 7.1, http://www.targetscan.org55; MicroRNA Target 
Prediction and Functional Study Database [miRDB], http://mirdb.org/miRDB56; RNA22 version 2.0, https://cm.
jefferson.edu/rna22/57). We considered genes to be a potential target of an miRNA when predicted by all three 
databases and when the binding site was a conserved site within the 3′ UTR region.
Survival data. MFS was defined as the time elapsed between the date of surgery and either the date of the 
appearance of distant metastasis or the date of the last follow-up visit at which a patient was considered to have no 
recurrence. HFS was defined as the time elapsed between the date of surgery and either the date of the appearance 
of liver metastasis or the date of the last follow-up visit at which a patient was considered to have no liver metasta-
ses. OS was defined as the time elapsed between the date of surgery and either the date of death or the date of the 
last check in the Municipal Personal Records Database.
Statistical analysis. Statistical analyses were performed using SPSS statistical package version 21. 
Associations between the expression of the six miRNAs as continuous variables and clinical and histopathologi-
cal characteristics were assessed using the Mann-Whitney U test, Spearman Rank correlation test, Kruskal-Wallis 
test, and Jonckheere-Terpstra test as appropriate. Cox regression analysis was used to assess the association 
between the expression of the six miRNAs as continuous variables and MFS, HFS, and OS. A one-way ANOVA 
was used to assess the difference between the two log likelihood estimates of the Cox regression models when 
adding a variable to the model. Kaplan Meier estimates were used to visualize the relevant associations between 
the miRNAs and long-term clinical outcome. Youden’s index was calculated as described previously20. All analy-
ses were two-sided and P < 0.05 considered significant.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files. The RNA sequencing data were published previously and made available 
elsewhere50.
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